Aldeyra Therapeutics, Inc.
ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administā¦ read more
Healthcare
Biotechnology
9 years
USD
44
/100
Price
per share adjusted in USD$2.56
Price+5.58%
$0.14
5Y
Price
Market Cap
$152.556m
Small
Price/Earnings
-5x
-
3y Avg-
5y AvgDividends
Ex-Dividend: -0.00%
Yield$0.00
Dividend0.00%
Forward Dividend Growth
-
-
3y CAGR-
5y CAGRPayout
0.00%
-
Payout 3y-
Payout 5yYield
BenchmarkDividends
No items found.
Financials Overview
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$392.620k
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$37.870m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$0.64
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$98.310m
$126.044m
Assets$27.734m
Liabilities$15.636m
DebtDebt to Assets
12.4%
-0.4x
Debt to EBITDAFree Cash Flow
-$30.721m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metricsNo items found.
Press Releases